Literature DB >> 16983740

Current role of radiofrequency ablation for the treatment of colorectal liver metastases.

A McKay1, E Dixon, M Taylor.   

Abstract

BACKGROUND AND
METHOD: This paper reviews the current status of radiofrequency ablation in the treatment of colorectal liver metastases. Relevant studies with at least ten patients that reported rates of complete tumour ablation, local recurrence, or survival from 1 to 5 years after treatment were included in the review. RESULTS AND
CONCLUSION: Only six studies that reported at least 3-year survival were identified, with results ranging from 37 to 58 per cent. Some of these figures are promising, given that the patients were considered to have unresectable disease. However, available evidence is limited and hepatic resection remains the standard of care when feasible; radiofrequency ablation cannot be considered an equivalent. Radiofrequency ablation does, however, appear to have a role in treating unresectable disease, and may also be used in conjunction with resection to extend its limits.

Entities:  

Mesh:

Year:  2006        PMID: 16983740     DOI: 10.1002/bjs.5581

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  19 in total

1.  Computed tomography (CT)-guided versus laparoscopic radiofrequency ablation: a single-institution comparison of morbidity rates and hospital costs.

Authors:  Maria A Cassera; Kevin W Potter; Michael B Ujiki; Lee L Swanström; Paul D Hansen
Journal:  Surg Endosc       Date:  2010-09-17       Impact factor: 4.584

2.  Long-term survival following radiofrequency ablation of colorectal liver metastases: A retrospective study.

Authors:  Simeon Niyi Babawale; Thomas Mandøe Jensen; Jens Brøndum Frøkjær
Journal:  World J Gastrointest Surg       Date:  2015-03-27

3.  Hepatectomy is superior to thermal ablation for patients with a solitary colorectal liver metastasis.

Authors:  Suzanne Claire Schiffman; Matthew Bower; Russell E Brown; Robert C G Martin; Kelly M McMasters; Charles R Scoggins
Journal:  J Gastrointest Surg       Date:  2010-09-22       Impact factor: 3.452

4.  Radiofrequency ablation of liver tumors: Actual limitations and potential solutions in the future.

Authors:  Beat M Künzli; Paolo Abitabile; Christoph A Maurer
Journal:  World J Hepatol       Date:  2011-01-27

5.  Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases.

Authors:  Sanghwa Ko; Hongjae Jo; Seongpil Yun; Eunyoung Park; Suk Kim; Hyung-Il Seo
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

6.  Radiofrequency ablation vs. hepatic resection for resectable colorectal liver metastases.

Authors:  Nan He; Qian-Na Jin; Di Wang; Yi-Ming Yang; Yu-Lin Liu; Guo-Bin Wang; Kai-Xiong Tao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

7.  Early postoperative outcomes following hepatic resection for benign liver disease in 79 consecutive patients.

Authors:  Jeffrey T Lordan; Tim R Worthington; Nial Quiney; William Fawcett; Nariman D Karanjia
Journal:  HPB (Oxford)       Date:  2009-06       Impact factor: 3.647

8.  Perinecrotic hypoxia contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases.

Authors:  Jarmila D W van der Bilt; Marije E Soeters; Annique M M J Duyverman; Maarten W Nijkamp; Petronella O Witteveen; Paul J van Diest; Onno Kranenburg; Inne H M Borel Rinkes
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

9.  Operative mortality, blood loss and the use of Pringle manoeuvres in 526 consecutive liver resections.

Authors:  Jeffrey T Lordan; Tim R Worthington; Nial Quiney; William J Fawcett; Nariman D Karanjia
Journal:  Ann R Coll Surg Engl       Date:  2009-08-14       Impact factor: 1.891

10.  Complementary use of resection and radiofrequency ablation for the treatment of colorectal liver metastases: an analysis of 395 patients.

Authors:  Orhan Agcaoglu; Shamil Aliyev; Koray Karabulut; Galal El-Gazzaz; Federico Aucejo; Robert Pelley; Allan E Siperstein; Eren Berber
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.